Each gram of Rosac® Cream With Sunscreens contains 100 mg of sodium sulfacetamide and 50 mg of sulfur in a cream base.
Rosac Cream With Sunscreens is indicated in the topical control of acne vulgaris, acne rosacea and seborrheic dermatitis.
Media Articles Related to Rosac (Sodium Sulfacetamide / Sulfur)
Ivermectin 1% Cream for Rosacea
Source: Medscape Allergy & Clinical Immunology Headlines [2015.11.23]
Is the anti-parasitic and anti-inflammatory agent ivermectin an effective treatment for rosacea?
Skin Therapy Letter
Rosacea Caused Half by Nature, Half by Lifestyle: Study
Source: MedicineNet Rosacea Specialty [2015.09.09]
Title: Rosacea Caused Half by Nature, Half by Lifestyle: Study
Category: Health News
Created: 9/9/2015 12:00:00 AM
Last Editorial Review: 9/9/2015 12:00:00 AM
FDA Approves New Rosacea Treatment
Source: MedicineNet Rosacea Specialty [2015.08.04]
Title: FDA Approves New Rosacea Treatment
Category: Health News
Created: 8/3/2015 12:00:00 AM
Last Editorial Review: 8/4/2015 12:00:00 AM
Once-Daily Ivermectin Is a Safe Rosacea Treatment
Source: MedicineNet metronidazole cream Specialty [2015.04.02]
Title: Once-Daily Ivermectin Is a Safe Rosacea Treatment
Category: Health News
Created: 4/2/2015 12:00:00 AM
Last Editorial Review: 4/2/2015 12:00:00 AM
Source: MedicineNet adapalene Specialty [2015.02.18]
Category: Diseases and Conditions
Created: 12/31/1997 12:00:00 AM
Last Editorial Review: 2/18/2015 12:00:00 AM
Published Studies Related to Rosac (Sodium Sulfacetamide / Sulfur)
Combination sodium sulfacetamide 10% and sulfur 5% cream with sunscreens versus metronidazole 0.75% cream for rosacea. [2005.06]
Topical metronidazole and combination sodium sulfacetamide and sulfur commonly are used to treat rosacea. Recently, the relative efficacy and safety of sodium sulfacetamide 10% and sulfur 5% cream with sunscreens (Rosac Cream) (n = 75) and metronidazole 0.75% cream (Metrocream) (n = 77) were compared in an investigator-blinded, randomized, parallel-group study at 6 sites...
Topical rosacea therapy: the importance of vehicles for efficacy, tolerability and compliance. [2011.06]
Many topical medications are available for the treatment of papulopustular rosacea. While treatments contain metronidazole, azelaic acid, or sodium sulfacetamide-sulfur as the active ingredient, the composition of the vehicle formulations varies widely... This review will focus on the key components of the vehicles from the most commonly used topical therapies for papulopustular rosacea and how vehicle formulations influence the delivery of active ingredient, skin barrier repair, tolerability and compliance.
Effectiveness and safety of doxycycline 40 mg (30-mg immediate-release and 10-mg delayed-release beads) once daily as add-on therapy to existing topical regimens for the treatment of papulopustular rosacea: results from a community-based trial. [2010.11]
Rosacea is a prevalent inflammatory skin disorder that affects approximately 16 million individuals in the United States. Although its exact etiology is unknown, basic science, histologic evidence, and clinical evidence suggest that it is inflammatory in nature... Thus the 40-mg formulation of doxycycline proved to be effective and well-tolerated in a real-world setting in participants with rosacea who were receiving topical therapy but still experiencing symptoms.
The multifunctionality of 10% sodium sulfacetamide, 5% sulfur emollient foam in the treatment of inflammatory facial dermatoses. [2010.03]
Prior to 1962, some of the most versatile drugs in dermatology were approved by the U.S...
Updates on the pathophysiology and management of acne rosacea. [2009.09]
There are many options for the treatment of acne rosacea, including topical and systemic therapies, laser and light-based therapies, and surgical procedures. A classification system for rosacea identifies 4 subtypes (ie, erythematotelangiectatic, papulopustular, phymatous, and ocular), which may help guide therapeutic decision making...
Clinical Trials Related to Rosac (Sodium Sulfacetamide / Sulfur)
RosaC-RF : Bipolar Radiofrequency vs Doxycycline in Rosacea [Recruiting]
Rosacea is a chronic facial disfiguring dermatosis characterized by different stages like
flushing, erythema, telangiectasia and papulo-pustular lesions. Recommended treatments
include topical (metronidazole) and systemic (doxycycline) antibiotics with only a
suspensive effect. The bipolar radiofrequency (RF) with Elos system (infrared light) is a
device emitting an electromagnetic current inducing an increase in temperature when applied
on the skin, potentiated by infrared light. The monopolar RF has already been used in
rosacea on a small number of cases with positive and prolonged results. RF with Elos system
has been evaluated on erythemato-telangiectasic rosacea with encouraging results. Demodex
folliculorum (DF) is a long transparent mite which asymptomatically parasitizes
pilosebaceous follicle of normal human skin sometimes responsible of inflammatory facial
dermatoses. The prevalence and density of DF are increased in rosacea, and DF is suspected
to play a role in the pathogenesis of rosacea. DF is sensitive to heat, and the
investigators hypothesize that radiofrequency treatment may affect the survival of the mite
and should be effective to treat papulopustular rosacea.
Antidepressants During Pregnancy and Lactation: Pharmacokinetics and Clinical Implications [Recruiting]
Background: The childbearing years are a time of increased vulnerability to the onset of
mood disorders in women and a high prevalence of exposure to antidepressant drugs during
pregnancy and postpartum has been reported. However, the lack of information regarding the
milk transfer and the safety of these drugs in breastfed infants and the related fear of
adverse events for the sucking infant are some of the factors responsible for stopping
prematurely breast-feeding or avoiding drug therapy. Selective serotonin reuptake inhibitors
(SSRI) and selective serotonin and noradrenaline reuptake inhibitors (SNRI) are the most
frequently prescribed antidepressant drugs during pregnancy and the post-partum period. They
exhibit a wide interpatient variability in their concentration profiles that has been
related to numerous environmental, stereochemical, demographic and genetic influences that
might alter the level of exposure of breastfed newborns. Limited information is available
regarding the safety of use of these antidepressant drugs during lactation, and is generally
derived from small studies. A comprehensive description of their distribution and
quantification in milk in a larger cohort of patients under various influences and the
resulting impact on milk concentrations is lacking.
Objectives: The current proposal addresses the primary objectives of quantifying the range
of concentration to citalopram, escitalopram, sertraline, fluoxetine, paroxetine,
fluvoxamine, duloxetine and venlafaxine in mother plasma and breast milk in relation to
genetic polymorphisms, stereochemistry, demographics and environmental factors in a large
cohort of depressive mothers. This will enable to derive the exposure to the breast-fed
child taking into account this variability and therefore better adjust treatment to
potential influences. As secondary objectives, we will examine the neurodevelopmental
outcome of a sub-set of infants subjected to SSRI/SNRI in utero and/or during breastfeeding
at birth, 6, 18 and 36 months, and compared to that of a control population of infants not
subjected to this treatment.
Expected Results: The proposed strategy will offer new information regarding the expected
level of drug exposure associated with each or with a combination of risk factors and help
for optimizing the security and rationalizing the use of antidepressant treatment in
lactating women. Hence, research on the safety of use of these drugs for the developing
child is an area of great public health significance.
Very Preterm Children With Language Delay and Parent Intervention [Recruiting]
In studies of children born at term, language delay at the age of 2 years exhibits a
spontaneously favourable course in 30 to 50% by the age of 3 years. In France, there is no
recommendation for speech therapy before the age of 3 years. However, for term-born
children, parent-implemented language interventions conducted during the third year of life
have already shown a positive short-term effect on language skills. In these interventions,
a skilled interventionist, generally a speech therapist, teaches parents how to use specific
language strategies with their child.
The investigators' hypothesis is that such parent-implemented interventions would be
particularly appropriate at short and medium term for the improvement of linguistic
performances in very preterm children, a population with a high prevalence of early language
delay. Currently, there is an opportunity to partly nest an intervention trial in a national
prospective population-based cohort of very preterm children, the EPIPAGE (Etude
EPIdémiologique sur les Petits Ages GEstationnels) 2 cohort, which has included 5 000
babies born alive in France in 2011. This situation provides considerable methodological
Page last updated: 2015-11-23